Land: Australien
Språk: engelska
Källa: Department of Health (Therapeutic Goods Administration)
vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)
Pierre Fabre Australia Pty Ltd
Injection, concentrated
Excipient Ingredients: water for injections
Intravenous
1 x 5mL, 10 x 5mL
(S4) Prescription Only Medicine
Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.
Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Licence status A
2000-08-04